Tempus DPYD Algorithm

Tempus has added its DPYD algorithm to its portfolio of laboratory-developed tests. It can be used to evaluate relevant mutations in the dihydropyrimidine dehydrogenase gene and to better identify patients who may be at risk for potential toxicity from 5-FU/capecitabine chemotherapy. The algorithm is available as an add-on option for physicians ordering Tempus' xT solid tumor broad-panel assay.